The Goldman Sachs Group started coverage on shares of Beta Bionics (NASDAQ:BBNX - Free Report) in a report issued on Friday, MarketBeat.com reports. The firm issued a neutral rating and a $16.00 price target on the stock.
Several other research firms also recently commented on BBNX. Piper Sandler initiated coverage on Beta Bionics in a report on Monday, February 24th. They issued an "overweight" rating and a $26.00 target price on the stock. Bank of America assumed coverage on shares of Beta Bionics in a research note on Monday, February 24th. They issued a "buy" rating on the stock. Wolfe Research initiated coverage on shares of Beta Bionics in a research report on Friday. They set an "outperform" rating and a $20.00 price target for the company. Robert W. Baird initiated coverage on shares of Beta Bionics in a report on Thursday, February 20th. They issued a "neutral" rating and a $20.00 price objective for the company. Finally, Leerink Partners began coverage on Beta Bionics in a research report on Monday, February 24th. They issued an "outperform" rating and a $28.00 price objective on the stock. Four analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $23.13.
Get Our Latest Stock Analysis on BBNX
Beta Bionics Stock Performance
Shares of NASDAQ:BBNX traded down $0.20 during trading on Friday, hitting $18.49. The stock had a trading volume of 309,740 shares, compared to its average volume of 492,369. Beta Bionics has a 12 month low of $8.89 and a 12 month high of $24.50. The company has a fifty day moving average of $12.49.
Beta Bionics (NASDAQ:BBNX - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.01).
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BBNX. Rhumbline Advisers purchased a new position in shares of Beta Bionics in the 1st quarter worth $158,000. Strs Ohio bought a new position in Beta Bionics in the first quarter valued at about $29,000. Woodline Partners LP purchased a new position in Beta Bionics in the first quarter worth about $1,530,000. Goldman Sachs Group Inc. purchased a new position in Beta Bionics in the first quarter worth about $715,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Beta Bionics during the 1st quarter valued at about $95,000.
Beta Bionics Company Profile
(
Get Free Report)
Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.
Recommended Stories
Before you consider Beta Bionics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Beta Bionics wasn't on the list.
While Beta Bionics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
